Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

The mechanism of action of cidabenamide and the advantages of vincristine metronomic chemotherapy make it possible to combine the two drugs. Therefore, it is necessary to conduct a prospective study to investigate the value of chidamide in combination with vincristine metronomic treatment for triple-negative breast cancer.

Inclusion Criteria:female;aged ≥ 18 years and ≤75 years;histologically proved metastatic triple-negative breast cancer;at least one measurable or evaluable lesion based on RECIST 1.1 criteria;estimated life expectancy ≥ 3 months; (6) normal heart, liver, and kidney function;Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; -informed consent signed by the participants.Exclusion Criteria:received neoadjuvant or adjuvant therapy containing vinorelbine or capecitabine within one year prior to treatment initiation;participated in other new drug clinical trials within 4 weeks before enrollment;inflammatory breast cancer;symptomatic visceral disease;second primary malignancy;mental disorder.